flexion therapeutics inc  product pipeline review    compare about us  contact us home research category publisher list custom research cart compare research category user guide policies contact us about us site map home  market research report  pharmaceutical  pharmaceutical companies  pharma info market research report flexion therapeutics inc  product pipeline review   published by global markets direct product code  published september   content info  pages price usd  pdf by email single user license usd  pdf by email site license usd  pdf by email global license flexion therapeutics inc  product pipeline review   published september   content info  pages description summary global markets directs flexion therapeutics inc  product pipeline review   provides an overview of the flexion therapeutics incs pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of flexion therapeutics incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope the report provides brief overview of flexion therapeutics inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of flexion therapeutics incs human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement latest news and deals relating to the flexion therapeutics incs pipeline products reasons to buy evaluate flexion therapeutics incs strategic position with total access to detailed information on its product pipeline assess the growth potential of flexion therapeutics inc in its therapy areas of focus identify new drug targets and therapeutic classes in the flexion therapeutics incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of flexion therapeutics inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of flexion therapeutics inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of flexion therapeutics inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contents product code gmdhccdbtable of contents table of contents list of tables list of figures flexion therapeutics inc snapshot flexion therapeutics inc overview key information key facts flexion therapeutics inc  research and development overview key therapeutic areas flexion therapeutics inc  pipeline review pipeline products by stage of development pipeline products  monotherapy flexion therapeutics inc  pipeline products glance flexion therapeutics inc  late stage pipeline products phase iii productscombination treatment modalities flexion therapeutics inc  clinical stage pipeline products phase ii productscombination treatment modalities flexion therapeutics inc  early stage pipeline products preclinical productscombination treatment modalities flexion therapeutics inc  unknown stage pipeline products unknown productscombination treatment modalities flexion therapeutics inc  drug profiles triamcinolone acetonide sodium phosphate sr product description mechanism of action rd progress fx product description mechanism of action rd progress fx product description mechanism of action rd progress acamprosate calcium product description mechanism of action rd progress fx product description mechanism of action rd progress flexion therapeutics inc  pipeline analysis flexion therapeutics inc  pipeline products by target flexion therapeutics inc  pipeline products by route of administration flexion therapeutics inc  pipeline products by molecule type flexion therapeutics inc  pipeline products by mechanism of action flexion therapeutics inc  recent pipeline updates flexion therapeutics inc  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tables flexion therapeutics inc key information flexion therapeutics inc key facts flexion therapeutics inc  pipeline by indication  flexion therapeutics inc  pipeline by stage of development  flexion therapeutics inc  monotherapy products in pipeline  flexion therapeutics inc  phase iii  flexion therapeutics inc  phase ii  flexion therapeutics inc  preclinical  flexion therapeutics inc  unknown  flexion therapeutics inc  pipeline by target  flexion therapeutics inc  pipeline by route of administration  flexion therapeutics inc  pipeline by molecule type  flexion therapeutics inc  pipeline products by mechanism of action  flexion therapeutics inc  recent pipeline updates  list of figures flexion therapeutics inc  pipeline by top  indication  flexion therapeutics inc  pipeline by stage of development  flexion therapeutics inc  monotherapy products in pipeline  flexion therapeutics inc  pipeline by top  target  flexion therapeutics inc  pipeline by top  route of administration  flexion therapeutics inc  pipeline by top  molecule type  flexion therapeutics inc  pipeline products by top  mechanism of action  phone intl  tollfreeus  europe  asia  new for   gii now purchases any market research reports from any publishers for you with noextra cost contact us for more details faq delivery time user license payment options compare multiple reports about contact user guide policies site map  copyright  global information inc all rights reserved flashratings  principles facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings principles  flashratings mission is to provide you  the investor  with as much honest and professional research on your investments as possible  we believe its much better to get a multitude of credible opinions on an investment than to arbitrarily follow any single advisor  be it your banker a friend or a tv pundit  flashratings does not provide advice our job is to accurately and objectively report on analysts credible research and opinions the only advice flashratings will ever give you is to absorb as much fundamental research and different opinions as possible and make your own decisions  flashratings favors covering analysts with proven track records but will cover all analysts as long as their research is honest and professional sign up » flashratings  about us facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings  all research for my stocks the most comprehensive equity research coverage available online never miss a single piece of research upgrade downgrade or target price change by any analyst firm on any stock equity research by professional analysts  especially their rationales more than their forecasts  contains far more interesting and important information about the actual fundamentals of the traded companies than can be gathered from conventional news reports our mission is to unlock access to valuable research on stocks for all retail investors professionals institutions take advantage of our costeffective subscriptions to have flashratingss comprehensive realtime feed delivered into your intranet and trading floor platforms institutional subscriptions websites become a content licensing partner and display flashratingss popular news feed on your website content licensing advertisers advertise with us and have flashratings readers with attractive demographics take advantage of your products advertising flexion therapeutics inc  product pipeline review    reportsnreports market research report welcome guest    registerlogin   contact us   about us      advanced search home ›  pharmaceuticals ›  report detail flexion therapeutics inc  product pipeline review   published september  no of pages  price  single user license us   corporate user license us     report description table of contents inquire before buying global markets direct’s ‘flexion therapeutics inc  product pipeline review  ’ provides an overview of the flexion therapeutics inc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of flexion therapeutics inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescopethe report provides brief overview of flexion therapeutics inc including business description key information and facts and its locations and subsidiariesthe report reviews current pipeline of flexion therapeutics inc’s human therapeutic division and enlists all their major and minor projectsthe report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestonesspecial feature on outlicensed and partnered product portfoliothe report summarizes all the dormant and discontinued pipeline projectslatest company statementlatest news and deals relating to the flexion therapeutics inc’s pipeline productsreasons to buyevaluate flexion therapeutics inc’s strategic position with total access to detailed information on its product pipelineassess the growth potential of flexion therapeutics inc in its therapy areas of focusidentify new drug targets and therapeutic classes in the flexion therapeutics inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areasexploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gapsdevelop strategic initiatives by understanding the focus areas of flexion therapeutics inc and exploit collaboration and partnership opportunitiesidentify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantageplan mergers and acquisitions effectively by identifying the most promising pipeline of flexion therapeutics incdevelop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeexplore the dormant and discontinued projects of flexion therapeutics inc and identify potential opportunities in those areasavoid intellectual property rights related issues flexion therapeutics inc  product pipeline review   table of contentstable of contents list of tables list of figures flexion therapeutics inc snapshot flexion therapeutics inc overview key information key facts flexion therapeutics inc  research and development overview key therapeutic areas flexion therapeutics inc  pipeline review pipeline products by stage of development pipeline products  monotherapy flexion therapeutics inc  pipeline products glance flexion therapeutics inc  late stage pipeline products phase iii productscombination treatment modalities flexion therapeutics inc  clinical stage pipeline products phase ii productscombination treatment modalities flexion therapeutics inc  early stage pipeline products preclinical productscombination treatment modalities flexion therapeutics inc  unknown stage pipeline products unknown productscombination treatment modalities flexion therapeutics inc  drug profiles triamcinolone acetonide sodium phosphate sr product description mechanism of action rd progress fx product description mechanism of action rd progress fx product description mechanism of action rd progress acamprosate calcium product description mechanism of action rd progress fx product description mechanism of action rd progress flexion therapeutics inc  pipeline analysis flexion therapeutics inc  pipeline products by target flexion therapeutics inc  pipeline products by route of administration flexion therapeutics inc  pipeline products by molecule type flexion therapeutics inc  pipeline products by mechanism of action flexion therapeutics inc  recent pipeline updates flexion therapeutics inc  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesflexion therapeutics inc key information flexion therapeutics inc key facts flexion therapeutics inc  pipeline by indication  flexion therapeutics inc  pipeline by stage of development  flexion therapeutics inc  monotherapy products in pipeline  flexion therapeutics inc  phase iii  flexion therapeutics inc  phase ii  flexion therapeutics inc  preclinical  flexion therapeutics inc  unknown  flexion therapeutics inc  pipeline by target  flexion therapeutics inc  pipeline by route of administration  flexion therapeutics inc  pipeline by molecule type  flexion therapeutics inc  pipeline products by mechanism of action  flexion therapeutics inc  recent pipeline updates  list of figuresflexion therapeutics inc  pipeline by top  indication  flexion therapeutics inc  pipeline by stage of development  flexion therapeutics inc  monotherapy products in pipeline  flexion therapeutics inc  pipeline by top  target  flexion therapeutics inc  pipeline by top  route of administration  flexion therapeutics inc  pipeline by top  molecule type  flexion therapeutics inc  pipeline products by top  mechanism of action   published by global markets direct product code global markets direct did you find what you arewere looking for  if not read below and browse through other relevant pages for similar market research reports or get in touch with us through the formcontact info in your right navigation panel and well share relevant market report titles for you to explore related reports  global and japan hypolipidemic drugs market analysis report the global hypolipidemic drugs market is valued at xx million usd in  and is expected to reach xx million usd by the end of  growing at a cagr of xx between  and  japan plays an important role in global market with market size global and europe bacillus subtilis market  analysis and outlook to  this report presents a comprehensive overview of the bacillus subtilis market in europe this shares the history data information from  to  and forecast from  to  this report provides a detailed analysis of the market its dynam global and europe antipsychotic drugs market  analysis and outlook to  this report presents a comprehensive overview of the antipsychotic drugs market in europe this shares the history data information from  to  and forecast from  to  this report provides a detailed analysis of the market its dynam asiapacific vitamin  mineral supplement market by manufacturers regions type and application forecast to  watersoluble vitamins these vitamins pass in and out of the body easily most do not build up in the bodys cells watersoluble vitamins include vitamin c and the b vitamins thiamine riboflavin niacin pantothenic acid b biotin folic acid asiapacific pressure ulcer treatment products market by manufacturers regions type and application forecast to  pressure ulcer is an open wound on the skin pressure ulcer occurs due to the breakdown of skin and underlying tissues through excessive pressure on an area of the skin some of the symptoms of pressure ulcer are redness of the skin that worsens with asiapacific narcolepsy drug market by manufacturers regions type and application forecast to  narcolepsy is a longterm neurological disorder that involves a decreased ability to regulate sleepwake cycles symptoms include periods of excessive daytime sleepiness that usually last from seconds to minutes and may occur at any time about  o asiapacific maca extract market by manufacturers regions type and application forecast to  the root vegetable known as maca originates from the peruvian andes maca also known as peruvian ginseng is reported to have numerous health benefits in fact powdered maca is considered a unique superfood that boosts energy improves stamina and e asiapacific lipoic acid market by manufacturers regions type and application forecast to  lipoic acid is a vitaminlike compound found in a slightly yellow crystalline powder form it can be synthetically produced in laboratories for medical use but is found naturally in abundance in foods such as yeast liver kidney broccoli spinach global antipsychotic drugs detailed analysis report  this report splits antipsychotic drugs by product antipsychotic drugs product antidepressant antianxiety drugs this shares the history data information from  to  and forecast from  to  and this report mainly introduces volume  global sodium hyaluronate market professional survey report  this report studies sodium hyaluronate in global market especially in north america china europe southeast asia japan and india with production revenue consumption import and export in these regions from  to  and forecast to   why reportsnreportscom  market research reports and growing top fortune  organizations trust us for research data  support on call as well as emails your details are safe with us free support for your research requirements report delivery email delivery time upto  hrs  working days upto  hrs max  weekends and public holidays research support  custom research if this business study does not have the data and information analysis you need contact us with your research requirements we explore available market research reports to map your needs and share report titles with you alternatively we can also offer custom research that suits your budget and timelines share your information requirements here connect with us email salesreportsandreportscom call       home category publisher country latest reports markets discounted reports upcoming reports contact us subscription option using our subscription option you get access to market research reports and industry data of consumer goods market as per your needs get the best of consumer goods research reports by utilizing your research budgets in an optimum way more about our subscription option report alerts get email alerts about market research reports from industries and publishers of your interest please enter a valid email id thank you you have successfully subscribed to our report alerts avail upto  discount on below publisher reports technavio azoth analytics   reportsnreports all rights reserved disclamer privacy policy  terms and conditions  our market research blog  sitemap feeds rss  latest reports home  flexion transformative medicine where it matters flexion therapeutics is a specialty pharmaceutical company focused on the development and commercialization of novel local therapies for the treatment of patients with musculoskeletal conditions beginning with osteoarthritis oa a type of degenerative arthritis press releases featured activities   flexion therapeutics inc infoflexiontherapeuticscom  website design  development by graphic beans terms of use sitemap privacy policy connect with us × × × home  flexion transformative medicine where it matters flexion therapeutics is a specialty pharmaceutical company focused on the development and commercialization of novel local therapies for the treatment of patients with musculoskeletal conditions beginning with osteoarthritis oa a type of degenerative arthritis press releases featured activities   flexion therapeutics inc infoflexiontherapeuticscom  website design  development by graphic beans terms of use sitemap privacy policy connect with us × × × flexion therapeutics inc flxno company profile  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states profile flexion therapeutics inc flxno related topics stocksstock screenerhealthcarebiotechnology  medical research overview news key developments people charts financials analysts research pulse flxno on consolidated issue listed on nasdaq global market usd  jul  change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  full description flexion therapeutics inc incorporated on november   is a specialty pharmaceutical company the company is focused on the development and commercialization of therapies for the treatment of patients with musculoskeletal conditions beginning with osteoarthritis oa a type of degenerative arthritis and postoperative pain the companys portfolio of product candidates addresses the oa pain treatment spectrum from moderate to severe pain the companys lead product candidate zilretta also known as fx is a latestage injectable sustainedrelease intraarticular ia steroid for patients with moderate to severe oa pain the companys other product candidates include fx for postoperative pain and fx for the treatment of endstage oa patients the company has not generated any revenuezilrettathe company has designed zilretta to combine an administered steroid triamcinolone acetonide tca with poly lacticcoglycolic acid plga to provide sustained therapeutic concentrations in the joint and persistent analgesic effect the company has completed approximately five clinical trials in which a total of approximately  patients with oa of the knee were treated with zilrettafxfx is a preclinical smallmolecule tropomyosin receptor kinase a trka receptor antagonist designed to address postoperative pain trka is the receptor for nerve growth factor ngf a small peptide that is released following tissue injury fx is being developed to treat postoperative pain with target analgesia of  to  hours and is being formulated to remain in the tissues to provide pain relief for a period of time the company is conducting preclinical local pharmacology and toxicology experiments for fxfxfx is a sustainedrelease p mitogenactivated protein map kinase inhibitor the product has both analgesic and antiinflammatory properties the company intends to seek partners for out licensing opportunities for fxthe company competes with anika therapeutics inc carbylan therapeutic actavis plc hanmi pharmaceuticals co ltd tissuegene inc ampio pharmaceuticals inc orthotrophix merck serono abbvie menarini donga mariel therapeutics samumed allergan inc eupraxia pacira pharmaceuticals durect corporation innocoll ag and omeros » full overview of flxno company address flexion therapeutics inc  mall rd ste burlington   ma    p f  company web links home page officers  directors name compensation patrick mahaffy  michael clayman  mark levine  neil bodick  john magee  » more officers  directors flexion therapeutics inc news briefflexion therapeutics files for stock shelf of upto  mln jun   briefflexion therapeutics qtrly loss per share  may   briefflexion therapeutics announces pricing of  mln of senior notes apr   briefflexion expects to have  mln in cash cash equivalents and marketable securities as of march  apr   briefflexion therapeutics announces proposed convertible senior notes offering apr   » more flxno news related topics stocksstock screenerhealthcarebiotechnology  medical research flxn key statistics  flexion therapeutics inc financial ratios  marketwatch bulletin investor alert new york markets after hours market snapshot winners and losers expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close flexion therapeutics inc nasdaq flxn go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus flexion therapeutics inc after hours  real time quotes jul    pm flxn quoteszigmancomposite   change   volume volume  real time quotes quoteszigmancomposite todays close     change   day low day high    week low  week high   company description flexion therapeutics inc is a pharmaceutical company which focuses on the development and commercialization of novel local therapies the firm specializes in treatment of patients with musculoskeletal conditions including osteoarthritis it offers products under the zilretta brand the company  flexion therapeutics inc is a pharmaceutical company which focuses on the development and commercialization of novel local therapies the firm specializes in treatment of patients with musculoskeletal conditions including osteoarthritis it offers products under the zilretta brand the company was founded by michael d clayman and neil bodick on november   and is headquartered in burlington ma valuation pe current  pe ratio with extraordinary items  price to book ratio  enterprise value to ebitda  total debt to enterprise value  efficiency income per employee  liquidity current ratio  quick ratio  cash ratio  profitability return on assets  return on equity  return on total capital  return on invested capital  capital structure total debt to total equity  total debt to total capital  total debt to total assets  longterm debt to equity  longterm debt to total capital  officers and executives name age officer since title dr michael d clayman   president chief executive officer cfo  director dr neil bodick   chief scientific officer ms carolyn beaty scimemi   chief compliance officer mr dan leblanc   senior vice presidentcmc operations insider actions – purchase – sale  – number of transactions  date name shares transaction value  michael d clayman president and ceo director      mark p stejbach director    acquisition at  per share   michael d clayman president and ceo director    acquisition at  per share   neil bodick chief medical officer    disposition at  per share   neil bodick chief medical officer    disposition at  per share   neil bodick chief medical officer    derivativenonderivative trans at  per share   neil bodick chief medical officer    disposition at  per share   neil bodick chief medical officer    disposition at  per share   neil bodick chief medical officer    derivativenonderivative trans at  per share   frederick w driscoll chief financial officer    disposition at  per share   frederick w driscoll chief financial officer    derivativenonderivative trans at  per share   neil bodick chief medical officer    disposition at  per share   neil bodick chief medical officer    derivativenonderivative trans at  per share   frederick w driscoll chief financial officer    disposition at  per share   frederick w driscoll chief financial officer    disposition at  per share   frederick w driscoll chief financial officer    derivativenonderivative trans at  per share   neil bodick chief medical officer    disposition at  per share   neil bodick chief medical officer    derivativenonderivative trans at  per share   neil bodick chief medical officer    disposition at  per share  newslatestcompanyusflxn marketwatch news on flxn flexion therapeutics started at strong buy with  stock price target at raymond james  am dec    tomi kilgore conagra rallies on earnings peabody tops losers  pm sept    sue chang united natural shares surge on earnings outlook beat  pm sept    wallace witkowski newsnonmarketwatchcompanyusflxn other news on flxn the zacks analyst blog highlights valeant pharmaceuticals international flexion therapeutics ignyta and anika therapeutics  am july    zackscom  sellranked drug stocks to avoid ahead of q earnings  am july    zackscom why this biotech could be poised for a run after toppling  in june  pm july    investors business daily flexion therapeutics flxn investor presentation  slideshow  pm july    seeking alpha biotech forum daily digest  ipo activity increasing spotlight on flexion therapeutics  pm july    seeking alpha flexion therapeutics flexin its price target  am july    seeking alpha why flexion therapeutics rallied  in june  pm july    motley fool biotechs gained  billion last week — can they keep going  pm july    investors business daily the investment case for flexion therapeutics  pm june    seeking alpha flexion looks good with upcoming fda catalyst  am june    seeking alpha my biggest mistake sticking with gilead too long bret jensen  am june    seeking alpha  small biotechs that could soar in second half of   pm june    seeking alpha biotech forum daily digest medicare cuts looming spotlight on invuity  am may    seeking alpha economic analysis shows cost effectiveness of flexions zilretta for treating knee osteoarthritis pain shares up   pm may    seeking alpha eam investors llc buys newlink genetics corp teladoc inc esperion therapeutics inc sells   pm may    gurufocuscom flexion therapeutics flxn ceo mike clayman on q  results  earnings call transcript  pm may    seeking alpha why vwr corp is soaring today  pm may    motley fool why flexion therapeutics inc stock is tanking  am april    motley fool flexion readies m convertible debt offering shares down  after hours  pm april    seeking alpha why flexion therapeutics new pain drug could be a gamechanger  pm april    motley fool loading more headlines at a glance flexion therapeutics inc  mall road suite  burlington massachusetts  phone   industry pharmaceuticals sector health carelife sciences fiscal yearend  view sec filings revenue na net income m employees  annual report for flxn newspressreleasecompanyusflxn press releases on flxn flexion therapeutics to hold investor  analyst day today  am july    globenewswire flexion therapeutics to hold investor and analyst day on july    am july    globenewswire flexion therapeutics announces appointment of mark levine as general counsel  am june    globenewswire flexion therapeutics named one of boston business journals best places to work  am june    globenewswire flexion therapeutics to present data on zilrettatm fx at the american diabetes associations th scientific sessions  pm june    globenewswire flexion to present new costeffectiveness data on zilrettatm fx at the international society for pharmacoeconomics and outcomes research nd international meeting  am may    globenewswire how these generic drugs stocks are faring  myos rens technology akari therapeutics flexion therapeutics and zynerba pharma  am may    pr newswire  prf flexion therapeutics announces upcoming data presentation at the american diabetes associations th scientific sessions  am may    globenewswire scientistcom raises m to expand next generation pharmaceutical outsourcing marketplace  am may    businesswire  bzx flexion therapeutics reports first quarter  financial results and recent business highlights  pm may    globenewswire investor network flexion therapeutics inc to host earnings call  am may    accesswire flexion therapeutics to present at the deutsche bank nd annual health care conference  am may    globenewswire flexion therapeutics highlights two clinical data presentations at the osteoarthritis research society international  world congress  am april    globenewswire flexion therapeutics announces pricing of  million  convertible senior notes due   pm april    globenewswire flexion therapeutics announces proposed convertible senior notes offering  pm april    globenewswire flexion therapeutics to report firstquarter  financial results on may    am april    globenewswire how these generic drugs stocks are faring  zynerba pharma patheon scynexis and flexion therapeutics  am april    pr newswire  prf flexion therapeutics announces appointment of yamo deniz md as chief medical officer  am april    globenewswire flexion therapeutics announces issuance of two new patents further strengthening intellectual property protection ip for zilrettatm fx  am april    globenewswire flexion therapeutics to present at needham  companys th annual healthcare conference  am march    globenewswire loading more headlines trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite tlt quoteszigmancomposite jnug x powered by log in  pm edt july   marketstatecountryus new york after marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pthe highest paid athletes in the world in one chart pwall street isn’t ready for a point tumble in the dow industrials phow to raise your kids to be frugal but not too frugal pcities to move to if you want to work in tech — not including san francisco pwhat donald trump’s battle of wills with jeff sessions teaches you about a difficult boss pone way you’re paying creditcard fees even if you don’t have a card ptrump russia and sanctions what we know pthis is the worst mistake people make at work pmove over breathalyzers ‘textalyzers’ could be used on drivers’ phones pjared kushner’s unorthodox approach to meetings is a cautionary tale for office workers everywhere phere’s how much you should spend on a yoga mat p weird things i found out about america in my first  hours pweekend sip is this the world’s first distilled nonalcoholic spirit pgoodyear stock stumbles  after quarter ‘played out differently than we expected’ ptime for gop to face reality everybody is going to have health insurance pbreakingdow industrials just  points shy of  milestone pwhy tax cuts for the rich solve nothing pcigarette maker stocks plunge on fda announcement but health experts are skeptical p‘game of thrones’ the four biggest takeaways from stormborn’ pamazon’s stock drop after results is the smallest in seven years loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one flexion therapeutics inc market  global product pipeline review    newswire flexion therapeutics inc market  global product pipeline review   press release  dec   december   press release  summary this report provides comprehensive information on the current therapeutic developmental pipeline of flexion therapeutics incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects browse here for full report  wwwacutemarketreportscomreportflexiontherapeuticsincproductpipelinereview acute market reportssreport features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsclick here for same category reports  wwwacutemarketreportscomcategoryhealthcaremarket note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope  the report provides brief overview of flexion therapeutics inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of flexion therapeutics incs human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement latest news and deals relating to the flexion therapeutics incs pipeline products reasons to buy  evaluate flexion therapeutics incs strategic position with total access to detailed information on its product pipeline assess the growth potential of flexion therapeutics inc in its therapy areas of focus identify new drug targets and therapeutic classes in the flexion therapeutics incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of flexion therapeutics inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of flexion therapeutics inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of flexion therapeutics inc and identify potential opportunities in those areas avoid intellectual property rights related issues request for free sample of this report  wwwacutemarketreportscomrequestfreesampleabout us acute market reports is the most sufficient collection of market intelligence services online it is your only source that can fulfill all your market research requirements we provide online reports from over  best publishers and upgrade our collection regularly to offer you direct online access to the worlds most comprehensive and recent database with expert perceptions on worldwide industries productsestablishments and trends our database consists of  market research report s with detailed  minute market research contact chris pauloffice no  st flooraditi mall baner punemh  indiaphone india  toll freeuscanadaemail salesacutemarketreportscomwebsite wwwacutemarketreportscom source url httpwwwmynewsdeskcominviewpressreleaseflexiontherapeuticsincmarketglobalproductpipelinereview share on facebook share on twitter categories arts and entertainment tags flexion therapeutics inc market more press releases formic acid npentyl ester market research report now available at acute market reports acutemarketreports  apr   global npentyl ester market  to   industry applications market size segmentation compandy share acute market reports acutemarketreports  apr   global ditertbutyl azodicarboxylatedbad market  to   industry share sizetrends and forecast by acute market reports acutemarketreports  apr   newswire get notified about new releases sign up for email updates from newswire enter your email address notification frequency press releases instant daily never news instant daily never event instant daily never blog daily never facebook daily never twitter daily never subscribe flashratings  contact us facebook autocomplete demo post a rating  month price target   trending sign up log in contact flashratings your emotional state excited confused worried upset panicked angry facebook autocomplete demo post a rating  month price target   home trending sign up log in analyst ranking   name measured ratings sucess rate avg return  mizuho      credit suisse      jefferies      cantor fitzgerald      bank of america merrill lynch      jmp securities      goldman sachs      raymond james      fbr capital markets      william blair     microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft flexion therapeutics inc  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports flexion therapeutics inc  product pipeline review   flexion therapeutics inc  product pipeline review   wgr  june  global  pages global markets direct description table of content sample report enquiry before buy related reports flexion therapeutics inc  product pipeline review  summaryglobal markets direct’s ‘flexion therapeutics inc  product pipeline review  ’ provides an overview of the flexion therapeutics inc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of flexion therapeutics inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of flexion therapeutics inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of flexion therapeutics inc’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the flexion therapeutics inc’s pipeline productsreasons to buy evaluate flexion therapeutics inc’s strategic position with total access to detailed information on its product pipeline assess the growth potential of flexion therapeutics inc in its therapy areas of focus identify new drug targets and therapeutic classes in the flexion therapeutics inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of flexion therapeutics inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of flexion therapeutics inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of flexion therapeutics inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contentstable of contents list of tables list of figures flexion therapeutics inc snapshot flexion therapeutics inc overview key information key facts flexion therapeutics inc  research and development overview key therapeutic areas flexion therapeutics inc  pipeline review pipeline products by stage of development pipeline products  monotherapy flexion therapeutics inc  pipeline products glance flexion therapeutics inc  clinical stage pipeline products phase ii productscombination treatment modalities flexion therapeutics inc  early stage pipeline products preclinical productscombination treatment modalities flexion therapeutics inc  unknown stage pipeline products unknown productscombination treatment modalities flexion therapeutics inc  drug profiles triamcinolone acetonide sr product description mechanism of action rd progress fx product description mechanism of action rd progress fx product description mechanism of action rd progress fx product description mechanism of action rd progress acamprosate product description mechanism of action rd progress fx product description mechanism of action rd progress flexion therapeutics inc  pipeline analysis flexion therapeutics inc  pipeline products by target flexion therapeutics inc  pipeline products by route of administration flexion therapeutics inc  pipeline products by molecule type flexion therapeutics inc  pipeline products by mechanism of action flexion therapeutics inc  recent pipeline updates flexion therapeutics inc  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesflexion therapeutics inc key information flexion therapeutics inc key facts flexion therapeutics inc  pipeline by indication  flexion therapeutics inc  pipeline by stage of development  flexion therapeutics inc  monotherapy products in pipeline  flexion therapeutics inc  phase ii  flexion therapeutics inc  preclinical  flexion therapeutics inc  unknown  flexion therapeutics inc  pipeline by target  flexion therapeutics inc  pipeline by route of administration  flexion therapeutics inc  pipeline by molecule type  flexion therapeutics inc  pipeline products by mechanism of action  flexion therapeutics inc  recent pipeline updates  list of figuresflexion therapeutics inc  pipeline by top  indication  flexion therapeutics inc  pipeline by stage of development  flexion therapeutics inc  monotherapy products in pipeline  flexion therapeutics inc  pipeline by top  target  flexion therapeutics inc  pipeline by top  route of administration  flexion therapeutics inc  pipeline by top  molecule type  flexion therapeutics inc  pipeline products by top  mechanism of action   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send flexion therapeutics inc  flxn  stock price today  zacks quote overview stock activity open  day low  day high   wk low   wk high  avg volume  market cap  m dividend    beta  key earnings data earnings esp  most accurate est  current qtr est  current yr est  exp earnings date  prior year eps  exp eps growth yrna forward pe na peg ratio na medical » medical  drugs zacks earnings esp expected surprise prediction looks to find earnings surprises by focusing on the most recent analyst revisions this is done because generally speaking if an analyst reevaluates their earnings estimate right before an earnings release it means that they have fresh information which could potentially be more accurate than what analysts thought about a company two or three months ago the crux of this approach is comparing the most accurate estimate to the zacks consensus estimate although the zacks rank is also an important feature of the esp metric combining these two can help investors find stocks that are ready to beat the consensus at their next report and hopefully surge higher in price too in fact when combining a zacks rank  or better and a positive earnings esp stocks produced a positive surprise  of the time and best of all by using these parameters investors have seen  annual returns on average according to our  year backtest visit the earnings esp center see the full list of stocks to beat earnings research report for flxn all zacks’ analyst reports premium research for flxn zacks rank sell  zacks industry rank bottom  out of  zacks sector rank bottom   out of  style scores f value  f growth  f momentum  f vgm earnings esp  research report for flxn snapshot this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn more about the zacks rank zacks rank home  all zacks rank resources in one place zacks premium  the only way to get access to the zacks rank the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank the zacks sector rank assigns a rating to each of the  sectors based on their average zacks rank a sector with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s zacks sector rank education  learn more about the zacks sector rank the sector with the best average zacks rank would be considered the top sector  out of  which would place it in the top  of zacks ranked sectors the sector with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks sector rank education  learn more about the zacks sector rank the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports zacks earnings esp expected surprise prediction looks to find companies that have recently seen positive earnings estimate revision activity the idea is that more recent information is generally speaking more accurate and can be a better predictor of the future which can give investors an advantage in earnings season the technique has proven to be very useful for finding positive surprises in fact when combining a zacks rank  or better and a positive earnings esp stocks produced a positive surprise  of the time while they also saw  annual returns on average according to our  year backtest visit the earnings esp center see the full list of stocks to beat earnings this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn more about the zacks rank zacks rank home  all zacks rank resources in one place zacks premium  the only way to fully access the zacks rank the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank the zacks sector rank assigns a rating to each of the  sectors based on their average zacks rank a sector with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s zacks sector rank education  learn more about the zacks sector rank the sector with the best average zacks rank would be considered the top sector  out of  which would place it in the top  of zacks ranked sectors the sector with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks sector rank education  learn more about the zacks sector rank the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the three scores are based on the trading styles of growth value and momentum growth score a value score a momentum score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b zacks style scores education  learn more about the zacks style scores the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports   change in last  days view all zacks rank  strong buys premium research industry analysis top peers symbol zacks rank flexion therapeutics inc flxn consort medical plc sponsored adr csrmy summit therapeutics plc smmt advanced accelerator applications sa aaap aerie pharmaceuticals inc aeri alcobra ltd adhd clinigen gp plc cligf see all medical  drugs peers zacks news for flxn  sellranked drug stocks to avoid ahead of q earnings am est zacks pharma stock roundup is sanofi buying flexion pfizer merck kgaa drug approved am est zacks flxn what are zacks experts saying now zacks private portfolio services flexion flxn stock soars  on  billion sanofi buyout pm est zacks how flexion flxn stock stands out in a strong industry am est zacks flexion therapeutics flxn stock moving average crossover alert am est zacks company summary flexion therapeutics inc is a specialty pharmaceutical company it is focused on the development and commercialization of injectable pain therapies the company is targeting antiinflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions it operates in the united states the companys product candidate fx is an injectable intraarticular meaning in the joint sustainedrelease treatment for patients with moderate to severe oa pain it is developing two additional product candidates fx for postoperative pain and fx to treat endstage oa patients flexion therapeutics inc is headquartered in burlington massachusetts news  flexion therapeutics inc new paradigms for the treatment of pain year all years         sort by date descending date ascending update   news   date title view jul   flexion therapeutics to hold investor  analyst day today management to discuss the latest plans for the potential launch of zilrettatmclinical experts to share perspectives on zilrettacompany to introduce new pipeline candidate fx burlington mass july   globe newswire  flexio pdf add to briefcase file is in briefcase jul   flexion therapeutics to hold investor and analyst day on july   burlington mass july   globe newswire  flexion therapeutics inc nasdaqflxn today announced that it will hold an investor and analyst day on monday july   flexion executives will discuss plans for commercializing zilretta™ fx the companys lead investigational product candidate for the tr pdf add to briefcase file is in briefcase jun   flexion therapeutics announces appointment of mark levine as general counsel burlington mass june   globe newswire  flexion therapeutics inc nasdaqflxn announced today that it has further strengthened its leadership team with the appointment of mark levine as senior vice president general counsel and secretary mr levine joins the companys impressive roster of industry veterans and pdf add to briefcase file is in briefcase jun   flexion therapeutics named one of boston business journals best places to work burlington mass june   globe newswire  flexion therapeutics inc nasdaqflxn today announced that it has been recognized as one of the the boston business journals best places to work flexion ranked th in the medium business category  to  employees and was presented with the awar pdf add to briefcase file is in briefcase jun   flexion therapeutics to present data on zilretta™ fx at the american diabetes associations th scientific sessions burlington mass june   globe newswire  flexion therapeutics inc nasdaqflxn will present the full results from a phase  study which found its lead investigational product candidate zilretta also known as fx was associated with reduced blood glucose bg elevation compared with immediate release triamcinol pdf add to briefcase file is in briefcase may   flexion to present new costeffectiveness data on zilretta™ fx at the international society for pharmacoeconomics and outcomes research nd international meeting findings suggest zilretta could potentially provide a costeffective treatment option for patients with osteoarthritis of the knee burlington mass may   globe newswire  flexion therapeutics inc nasdaqflxn today announced the findings from a new health economics analysis of zilr pdf add to briefcase file is in briefcase may   flexion therapeutics announces upcoming data presentation at the american diabetes associations th scientific sessions burlington mass may   globe newswire  flexion therapeutics inc nasdaqflxn today announced the upcoming presentation of the full results from a phase  clinical trial of its lead investigational product candidate zilretta™ fx in patients with type  diabetes and osteoarthritis oa of the knee the pdf add to briefcase file is in briefcase may   flexion therapeutics reports first quarter  financial results and recent business highlights capital infusion of approximately  million gross proceeds through recent offering of convertible senior notes expected to provide cash runway into new patents issued in us further strengthen intellectual property ip estate for zilretta™ fx our lead product candidatecl pdf add to briefcase file is in briefcase may   flexion therapeutics to present at the deutsche bank nd annual health care conference burlington mass may   globe newswire  flexion therapeutics inc nasdaqflxn today announced that michael clayman md president and chief executive officer and dan deardorf senior vice president commercial will present at the deutsche bank nd annual health care conference on wednesday may   at  pdf add to briefcase file is in briefcase apr   flexion therapeutics highlights two clinical data presentations at the osteoarthritis research society international  world congress in an analysis of pooled phase  data zilrettatm fx demonstrated clinically meaningful pain relief and functional improvement in patients with osteoarthritisa separate phase  study shows prolonged synovial localization and diminished systemic exposure of corticosteroid with zilretta compared pdf add to briefcase file is in briefcase apr   flexion therapeutics announces pricing of  million  convertible senior notes due  burlington mass april   globe newswire  flexion therapeutics inc nasdaqflxn today announced the pricing of  million aggregate principal amount of  convertible senior notes due  the notes in a private placement to qualified institutional bu pdf add to briefcase file is in briefcase apr   flexion therapeutics announces proposed convertible senior notes offering burlington mass april   globe newswire  flexion therapeutics inc nasdaqflxn today announced its intention to offer subject to market and other conditions  million principal amount of convertible senior notes due  the notes in a private offering to qualified institutional buyers pursuant to rul pdf add to briefcase file is in briefcase apr   flexion therapeutics to report firstquarter  financial results on may   burlington mass april   globe newswire  flexion therapeutics inc nasdaqflxn announced today that it will host a conference call and webcast to provide an update on business operations and report its firstquarter  financial results on thursday may   at  pm et the dialin number pdf add to briefcase file is in briefcase apr   flexion therapeutics announces appointment of yamo deniz md as chief medical officer burlington mass april   globe newswire  flexion therapeutics inc nasdaqflxn announced today that yamo deniz md has been named chief medical officer cmo this appointment strengthens the companys leadership with an industry veteran who brings extensive experience leading medical and clinical development te pdf add to briefcase file is in briefcase apr   flexion therapeutics announces issuance of two new patents further strengthening intellectual property protection ip for zilretta™ fx burlington mass april   globe newswire  flexion therapeutics inc nasdaqflxn today announced the us patent and trademark office has issued two new patents covering the companys lead investigational product candidate zilrettatm fx the new patents further strengthen the existing patent estate  pdf add to briefcase file is in briefcase mar   flexion therapeutics to present at needham  companys th annual healthcare conference burlington mass march   globe newswire  flexion therapeutics inc nasdaqflxn today announced that michael clayman md president and chief executive officer will present at needham  companys th annual healthcare conference on tuesday april   at  pm edt at the westin grand central hotel in new  pdf add to briefcase file is in briefcase mar   flexion reports yearend  financial results nda for zilrettatm fx filed in december  and accepted by fda in february pdufa action date set for october  commercialization plans on target for potential q launch of zilrettafrederick driscoll chief financial officer to retire eff pdf add to briefcase file is in briefcase mar   flexion therapeutics to present at upcoming investor conferences burlington mass march   globe newswire  flexion therapeutics inc nasdaqflxn today announced that michael clayman md president and chief executive officer will present at two upcoming investor conferences raymond james th annual institutional investors conference pdf add to briefcase file is in briefcase mar   flexion therapeutics to report yearend  financial results on march   burlington mass march   globe newswire  flexion therapeutics inc nasdaqflxn announced today that it will host a conference call and webcast to provide an update on business operations and report its fiscal year  financial results on thursday march   at  pm et the dialin number pdf add to briefcase file is in briefcase feb   flexion therapeutics initiates clinical trial to evaluate the safety of repeat administration of zilretta™ fx in patients with osteoarthritis of the knee burlington mass feb   globe newswire  flexion therapeutics inc nasdaqflxn today reported it has enrolled the first patient in a clinical trial to evaluate the safety of repeat administration of its investigational drug candidate zilretta also known as fx in patients with osteoarthritis oa of the knee th pdf add to briefcase file is in briefcase feb   flexion therapeutics to present at the rbc capital markets global healthcare conference burlington mass feb   globe newswire  flexion therapeutics inc nasdaqflxn today announced that michael clayman md president and chief executive officer will participate in an analystled fireside chat at the rbc capital markets global healthcare conference on wednesday february   at  am easte pdf add to briefcase file is in briefcase feb   flexion therapeutics announces new drug application for zilretta™ fx accepted by us food and drug administration fda reviewing zilretta as potential new treatment for osteoarthritis of the knee assigns pdufa date of october   burlington mass feb   globe newswire  flexion therapeutics inc nasdaqflxn today announced that the us food and drug administration  pdf add to briefcase file is in briefcase dec   flexion therapeutics submits new drug application for zilretta™ to treat knee osteoarthritis pain burlington mass dec   globe newswire  flexion therapeutics inc nasdaqflxn today announced it has submitted a new drug application nda to the us food and drug administration fda for its lead investigational product candidate zilretta also known as fx which is being evaluated to treat patients with  pdf add to briefcase file is in briefcase dec   flexion therapeutics to present at the bmo capital markets prescriptions for success healthcare conference burlington mass dec   globe newswire  flexion therapeutics inc nasdaqflxn today announced that michael clayman md president and chief executive officer will provide a company overview at the bmo capital markets prescriptions for success healthcare conference on wednesday december   at  am eas pdf add to briefcase file is in briefcase nov   flexion therapeutics announces pricing of public offering of common stock burlington mass nov   globe newswire  flexion therapeutics inc nasdaqflxn today announced the pricing of an underwritten public offering of  shares of its common stock at a price to the public of  per share  the gross proceeds from this offering are expected to be approximately  mil pdf add to briefcase file is in briefcase nov   flexion therapeutics announces proposed public offering of common stock burlington mass nov   globe newswire  flexion therapeutics inc nasdaqflxn today announced that it has commenced an underwritten public offering subject to market and other conditions to issue and sell shares of its common stock flexion also expects to grant the underwriters a day option to purchase addi pdf add to briefcase file is in briefcase nov   flexion therapeutics announces presentation of phase  data demonstrating that extendedrelease zilretta™ achieves clinically significant improvement of pain stiffness and function in patients with osteoarthritis of the knee dallas nov   globe newswire  flexion therapeutics inc nasdaqflxn announced today that its lead investigational product candidate zilretta also known as fx demonstrated clinically and statistically significant improvements in an analysis of phase  trial data conducted in patients with osteoarthritis oa o pdf add to briefcase file is in briefcase nov   flexion therapeutics reports third quarter  financial results successfully completed the transfer of the zilretta™ manufacturing technology to patheon  on track for nda submission in december met primary endpoint in clinical trial evaluating zilretta in type  diabetes patients with knee osteoarthritis  pdf add to briefcase file is in briefcase nov   flexion therapeutics announces that analysis from phase  clinical trial of zilretta™ for osteoarthritis of the knee to be presented at aahks burlington mass nov   globe newswire  flexion therapeutics inc nasdaqflxn today announced that further analysis of phase  data evaluating its investigational product zilretta™ also known as fx in patients with osteoarthritis oa of the knee will be presented during the th american  pdf add to briefcase file is in briefcase nov   flexion therapeutics reports primary endpoint met in clinical trial evaluating investigational drug candidate zilretta™ in type  diabetes patients with knee osteoarthritis   results demonstrate a markedly lower rise in blood glucose in patients receiving a zilretta injection compared to patients receiving an immediate release triamcinolone acetonide injection    difference was both statistically significant and clinically relevant   pdf add to briefcase file is in briefcase oct   flexion therapeutics to report thirdquarter  financial results on november   burlington mass oct   globe newswire  flexion therapeutics inc nasdaqflxn announced today that it will host a conference call and webcast to report its thirdquarter  financial results on monday november   at  pm etthe dialin number for the conference call is  for pdf add to briefcase file is in briefcase sep   flexion therapeutics announces appointment of john magee as vice president of sales burlington mass sept   globe newswire   pdf add to briefcase file is in briefcase sep   flexion therapeutics announces appointment of mark stejbach to its board of directors burlington mass sept   globe newswire   pdf add to briefcase file is in briefcase sep   flexion therapeutics announces two key corporate appointments burlington mass sept   globe newswire  flexion therapeutics inc nasdaqflxn announced today that it has made two key appointments to its leadership team carolyn beaty scimemi esq an experienced compliance and legal professional as chief compliance officer and adam muzikant phd a veteran biotechnol pdf add to briefcase file is in briefcase aug   flexion therapeutics to present at  wells fargo healthcare conference burlington mass aug   globe newswire  flexion therapeutics inc nasdaqflxn today announced that michael clayman md president and chief executive officer will provide a company overview at the th annual wells fargo securities healthcare conference on wednesday september   at  pm e pdf add to briefcase file is in briefcase aug   flexion therapeutics reports secondquarter  financial results positive data from completed pivotal phase b and phase  registration trials for zilretta™ flexions nonopioid lead drug candidate also known as fx presented at osteoarthritis research society international oarsi  world congress results demonstrated consistent efficacy across both studies with substan pdf add to briefcase file is in briefcase jul   flexion therapeutics to report secondquarter  financial results on august   burlington mass july   globe newswire  flexion therapeutics inc nasdaqflxn announced today that it will host a conference call and webcast to report its secondquarter  financial results on wednesday august   at  pm et the dialin number for the conference call is  pdf add to briefcase file is in briefcase jul   flexion therapeutics adds three new executives in key roles to support the planned commercial launch of zilretta™ burlington mass july   globe newswire   pdf add to briefcase file is in briefcase jun   flexion therapeutics announces pricing of public offering of common stock burlington mass june   globe newswire  flexion therapeutics inc nasdaq  pdf add to briefcase file is in briefcase jun   flexion therapeutics announces proposed public offering of common stock burlington mass june   globe newswire   pdf add to briefcase file is in briefcase may   flexion therapeutics receives positive guidance from fda on new drug application nda submission for zilretta™ for osteoarthritis of the knee burlington mass may   globe newswire   pdf add to briefcase file is in briefcase may   flexion therapeutics reports firstquarter  financial results zilretta™ flexions nonopioid lead drug candidate also known as fx completed pivotal phase b and phase  clinical registration trials in patients with osteoarthritis oa of the kneepositive data from these trials presented at the osteoarthritis research society international oarsi pdf add to briefcase file is in briefcase may   flexion therapeutics to report firstquarter  financial results on may   burlington mass may   globe newswire  flexion therapeutics inc nasdaqflxn announced today that it will host a conference call and webcast to report its firstquarter  financial results on thursday may   at  pm et the dialin number for the conference call is   for pdf add to briefcase file is in briefcase apr   flexion therapeutics enrolls first patient in phase  trial of zilretta™ among type  diabetes patients with knee osteoarthritis burlington mass april   globe newswire  flexion therapeutics inc nasdaqflxn today reported it has enrolled the first patient in a clinical trial to assess the effects of its lead drug candidate zilretta also known as fx on blood glucose levels in approximately  adults with osteoarthritis oa of the k pdf add to briefcase file is in briefcase apr   flexion therapeutics to present at th annual needham healthcare conference burlington mass april   globe newswire  flexion therapeutics inc nasdaqflxn today announced that michael clayman md president and chief executive officer will provide a company overview at the th annual needham healthcare conference on wednesday april   at  pm edt in new york pdf add to briefcase file is in briefcase apr   flexion therapeutics announces presentation of results from pivotal phase b and phase  clinical trials for zilretta™ at osteoarthritis research society international oarsi  world congress positive data from zilretta phase b and phase  clinical trials demonstrate consistent efficacy across both studies with substantial and persistent pain reliefin the phase  trial zilretta in contrast to immediaterelease triamcinolone acetonide tca exceeds american academy of orthopedic surgeons aa pdf add to briefcase file is in briefcase apr   flexion to present pivotal phase b and phase  results for zilretta™ at osteoarthritis research society international oarsi  world congress burlington mass april   globe newswire  flexion therapeutics inc nasdaqflxn today announced that it will rep pdf add to briefcase file is in briefcase mar   flexion reports yearend  financial results pivotal registration trials completed in patients with osteoarthritis oa of the knee for zilretta™ flexions lead drug candidate also known as fxzilretta received fasttrack designation by us food  drug administration fda in  planned nda submission on track for second half of  pdf add to briefcase file is in briefcase mar   flexion therapeutics to present at cowen and companys th annual health care conference burlington mass march   globe newswire  flexion therapeutics inc nasdaqflxn today announced that michael clayman md president and chief executive officer will provide a company overview at cowen and companys th annual health care conference on monday march   at  pm est at the pdf add to briefcase file is in briefcase mar   flexion therapeutics to report yearend  earnings results on march   burlington mass march   globe newswire  flexion therapeutics inc nasdaqflxn announced today that it will host a conference call and webcast to provide an update on business operations and report its yearend  financial results on thursday march   at  pm et the dialin numb pdf add to briefcase file is in briefcase feb   flexion therapeutics to present at rbc capital markets  global healthcare conference burlington mass feb   globe newswire  flexion therapeutics inc nasdaqflxn today announced that michael clayman md president and chief executive officer will participate in a fireside chat at the rbc capital markets  global healthcare conference on tuesday february   at  am eastern  pdf add to briefcase file is in briefcase feb   flexion therapeutics reports primary endpoint met in pivotal phase  trial of zilretta™ in knee osteoarthritis primary endpoint at week  against placebo achieved p value of  zilretta also achieved statistical significance on womac® a pain womac b stiffness and womac c  pdf add to briefcase file is in briefcase dec   flexion therapeutics to present at oppenheimer th annual healthcare conference burlington mass dec   globe newswire  flexion therapeutics inc nasdaqflxn today announced that michael clayman md president and chief executive officer will present at the oppenheimer th annual healthcare conference on tuesday december   at  am eastern time at the westin grand central pdf add to briefcase file is in briefcase dec   flexion therapeutics enrolls first patient in pharmacokinetic study of zilretta™ for osteoarthritis of the knee burlington mass dec   globe newswire  flexion therapeutics inc nasdaqflxn announced today that it has enrolled its first patient in a pharmacokinetic pk study of zilretta also known as fx in this openlabel single administration clinical trial researchers at four us sites will study  mg of zilre pdf add to briefcase file is in briefcase nov   flexion therapeutics to present at stifel  healthcare conference burlington mass nov   globe newswire  flexion therapeutics inc nasdaqflxn today announced that michael clayman md president and chief executive officer will present at the stifel  healthcare conference on tuesday november   at  am eastern time at the new york palace hotel in new yo pdf add to briefcase file is in briefcase nov   flexion therapeutics reports thirdquarter  financial results recent highlights secured a notice of allowance for the trademark zilretta™ previously known as fx from the united states patent and trademark office us ptoadvanced zilretta™ companys lead program with completion of patie pdf add to briefcase file is in briefcase nov   flexion therapeutics to report thirdquarter  financial results on november   burlington mass nov   globe newswire  flexion therapeutics inc nasdaqflxn announced today that it will host a conference call and webcast to report its thirdquarter  financial results on monday november   at  pm et the dialin number for the conference call is  pdf add to briefcase file is in briefcase sep   flexion therapeutics reports topline data from pivotal phase b clinical trial for fx − fx provides substantial and persistent pain relief compared to placebo welltolerated with safety profile comparable to placebo − conference call scheduled for tomorrow september   at  am et burlington mass sept   globe newswire  flexion therapeutics inc nasdaqflxn today reported topline r pdf add to briefcase file is in briefcase sep   flexion therapeutics granted fast track status by the fda for fx for treatment of osteoarthritis of the knee burlington mass sept   globe newswire  flexion therapeutics inc nasdaqflxn today announced that the us food and drug administration fda has granted fast track designation for fx flexions latestage lead drug candidate that is designed as a treatment for the more than four million us patients receiving intraarticular  pdf add to briefcase file is in briefcase aug   flexion therapeutics reports secondquarter  financial results recent highlightsadvanced fx companys lead program for the treatment of moderate to severe osteoarthritis oa pain by completing patient enrollment in phase  clinical trial ahead of schedule and preparing to announce topline pivotal data from phase b clinical trial in september also ahead of scheduleadded patheon as a contract manufactu pdf add to briefcase file is in briefcase aug   flexion therapeutics secures  million in debt financing nondilutive debt financing provides funding for manufacturing expansion for companys phase  lead clinical candidate fx for moderate to severe osteoarthritis oa pain burlington mass aug   globe newswire  flexion therapeutics inc nasdaqflxn today announced that it entered into a syndicated senior secured term loan fa pdf add to briefcase file is in briefcase aug   flexion therapeutics expands supply capacity for fx by entering into agreement with patheon  adding patheon as a contract manufacturer in addition to evonik corporation bolsters manufacturing capacity for planned commercialization of companys lead program burlington mass aug   globe newswire  flexion therapeutics inc nasdaqflxn today announced it has entered into a strategic manufacturing and supply agreement w pdf add to briefcase file is in briefcase jul   flexion therapeutics to report secondquarter  financial results on august   burlington mass july   globe newswire  flexion therapeutics inc nasdaqflxn announced today that it will host a conference call and webcast to report its secondquarter  financial results on thursday august   at  pm et the dialin number for the conference call is   for domestic participants and pdf add to briefcase file is in briefcase jul   flexion therapeutics completes enrollment in phase  clinical trial with lead compound fx in patients with osteoarthritis of the knee with rapid enrollment in phase  trial the company expects to report topline data in first quarter of  ahead of scheduletopline data from ongoing pivotal phase b clinical trial also expected to be reported earlier than planned burlington mass july   globe newswire  flexion therapeutics inc nasdaqflxn today announced th pdf add to briefcase file is in briefcase jun   flexion therapeutics final fx data from completed phase b doseranging trial published in journal of bone and joint surgery burlington mass june   globe newswire  flexion therapeutics inc nasdaqflxn today announced that a manuscript describing final study results from a completed phase b clinical trial of fx an intraarticular ia sustained release corticosteroid for the treatment of osteoarthritis oa has been published online in the journal  pdf add to briefcase file is in briefcase may   flexion therapeutics reports firstquarter  financial results key highlightsannounced a us department of defense dod grant worth approximately  million to conduct a phase  clinical trial to study lead compound fx in active military and medically retired veterans with posttraumatic osteoarthritis oaadvanced fx by initiating phase  clinical trial on schedule and completing enrollment in pivotal pdf add to briefcase file is in briefcase apr   flexion therapeutics to report firstquarter  financial results on may   burlington mass april   globe newswire  flexion therapeutics inc nasdaqflxn announced today that it will host a conference call and webcast to report its firstquarter  financial results on thursday may   at  pm et the dialin number for the conference call is   for domestic participants and  pdf add to briefcase file is in briefcase apr   flexion therapeutics awarded approximately  million from us department of defense to conduct clinical trial of fx in military personnel with osteoarthritis of the knee burlington mass april   globe newswire  flexion therapeutics inc nasdaqflxn today announced that the us department of defense dod awarded the company a grant worth approximately  million to conduct a phase  clinical trial investigating fx as treatment for osteoarthritis oa pain in active military and medically re pdf add to briefcase file is in briefcase apr   flexion therapeutics to present at th annual needham healthcare conference burlington mass april   globe newswire  flexion therapeutics inc nasdaqflxn today announced that michael clayman md president and chief executive officer will present at the th annual needham healthcare conference on wednesday april   at  am eastern time at the westin ny grand central hotel in new york ny  pdf add to briefcase file is in briefcase mar   flexion reports yearend  financial results strong cash position bolstered through ipo and followon financing raising a combined total of over  million lead drug candidate fx advanced into latestage pivotal trials for patients with osteoarthritis oa of the kneeburlington mass march   globe newswire  flexion therapeutics inc nasdaqflxn today announced financial  pdf add to briefcase file is in briefcase mar   flexion therapeutics to report yearend  earnings results on march   burlington mass march   globe newswire  flexion therapeutics inc nasdaqflxn announced today that it will host a conference call and webcast to report its yearend  financial results on monday march   at  pm et the dialin number for the conference call is   for domestic participants and   pdf add to briefcase file is in briefcase mar   flexion therapeutics announces changes to board of directors  scott canute former president of global manufacturing at eli lilly and company and subsequently at genzyme corporation appointed new board member  flexion ceo michael clayman offers thanks to departing board member andrew schwab  burlington mass march   globe newswire  flexion therapeutics inc nasdaqflxn announced today pdf add to briefcase file is in briefcase feb   flexion therapeutics completes enrollment in pivotal phase b confirmatory clinical trial with lead compound fx burlington mass feb   globe newswire  flexion therapeutics inc nasdaqflxn announced today that it has completed enrollment in its pivotal phase b confirmatory clinical trial designed to further evaluate the safety tolerability and efficacy of fx as a treatment for relieving pain associated with oa of the knee fx is flex pdf add to briefcase file is in briefcase feb   flexion therapeutics to present at rbc capital markets healthcare conference burlington mass feb   globe newswire  flexion therapeutics inc nasdaqflxn today announced that michael clayman md president and chief executive officer will present at the rbc capital markets healthcare conference on tuesday february   at  am eastern time at the new york palace hotel in new york ny to ac pdf add to briefcase file is in briefcase feb   flexion therapeutics initiates phase  clinical trial of fx in patients with osteoarthritis of the knee burlington mass feb   globe newswire  flexion therapeutics inc nasdaqflxn today announced dosing of the first patient in the phase  clinical trial of its lead drug candidate fx as a treatment for pain associated with osteoarthritis oa of the knee fx is flexions novel nonopioid sustainedrelease intraarticular ia  pdf add to briefcase file is in briefcase dec   flexion therapeutics announces exercise of underwriters overallotment option and closing of public offering of common stock burlington mass dec   globe newswire  flexion therapeutics inc nasdaqflxn today announced the closing of its previously announced underwritten public offering a total of  shares of the companys common stock were sold in the offering at a price to the public of  per share the shares include  shares of com pdf add to briefcase file is in briefcase dec   flexion therapeutics announces pricing of public offering of common stock burlington mass dec   globe newswire  flexion therapeutics inc nasdaqflxn today announced the pricing of its underwritten public offering of  shares of common stock at a price to the public of  per share flexion has also granted the underwriters a day option to purchase up to an additional  shares of co pdf add to briefcase file is in briefcase dec   flexion therapeutics announces public offering of common stock burlington mass dec   globe newswire  flexion therapeutics inc nasdaqflxn today announced that it is offering to sell  shares of common stock in an underwritten public offering flexion also expects to grant the underwriters a day option to purchase up to an additional  percent of the shares of common stock in the p pdf add to briefcase file is in briefcase dec   flexion therapeutics announces that fda has removed clinical hold on fx  company resumes recruitment in pivotal phase b trial initiation of phase  clinical trial planned for early  conference call scheduled for tomorrow december   at  am et burlington mass dec   globe newswire  flexion therapeutics inc nasdaqflxn today announced that the us food and drug administration f pdf add to briefcase file is in briefcase nov   flexion therapeutics to present at stifel healthcare conference  burlington mass nov   globe newswire  flexion therapeutics inc nasdaqflxn today announced that cfo frederick driscoll will present at the stifel healthcare conference  on wednesday november   at  pm eastern time the conference will take place at the new york palace hotel in new york city to access the liv pdf add to briefcase file is in briefcase nov   flexion therapeutics reports thirdquarter  financial results recent highlightsfollowing meeting with us food  drug administration fda announced plans to accelerate initiation of a phase  clinical trial for fxbolstered intellectual property ip protection for fx achieved progress in addressing questions related to fdas clinical hold of fx burlington mass nov   globe newswire pdf add to briefcase file is in briefcase nov   flexion therapeutics to report thirdquarter  financial results burlington mass nov   globe newswire  flexion therapeutics inc nasdaqflxn announced today that the company will host a conference call and webcast to report its thirdquarter  financial results on thursday november   at  pm eastern time the dialin number for the conference call is tollfree   pdf add to briefcase file is in briefcase sep   flexion therapeutics announces clinical hold of fx phase b clinical trial in osteoarthritis of the knee  company to host conference call tomorrow september   at  am et to discuss the clinical hold burlington mass sept   globe newswire  flexion therapeutics inc nasdaqflxn today announced that the united states food and drug administration fda informed the company yesterday that a clinical hold has been placed o pdf add to briefcase file is in briefcase sep   flexion therapeutics announces issuance of us composition of matter patent for lead candidate fx burlington mass sept   globe newswire  flexion therapeutics inc nasdaqflxn today announced that the us patent and trademark office has issued a composition of matter patent no  entitled corticosteroids for the treatment of joint pain which provides coverage for fx the companys lead clinical product candidate pdf add to briefcase file is in briefcase sep   flexion therapeutics to start fx phase  pivotal trial in  following fda meeting development plan advanced by one year  company to host conference call tomorrow september   at  am est during which management will discuss updated timing and plans burlington mass sept   globe newswire  based on a recent meeting with the us food and drug administration fda to review the clinical development program for flexions lead drug candidat pdf add to briefcase file is in briefcase aug   flexion therapeutics reports secondquarter  financial results recent highlightsannounced positive topline results from phase a synovial fluid pharmacokinetic pk study of lead clinical candidate fxinitiated confirmatory phase b clinical trial evaluating fx in patients with osteoarthritis oa of the kneeappointed two new directors to flexion boardrecently announced execution of southwest research ins pdf add to briefcase file is in briefcase jul   flexion therapeutics to report second quarter  financial results on august   burlington mass july   globe newswire  flexion therapeutics inc nasdaqflxn announced today that the company will host a conference call and webcast to report its second quarter  financial results on thursday august   at  pm et the dialin number for the conference call is tollfree   for domest pdf add to briefcase file is in briefcase jul   flexion therapeutics and southwest research instituter swrir sign worldwide exclusive license for proprietary microsphere manufacturing technologies flexion secures expanded intellectual property for manufacturing of fx sustained release microsphere drug candidate   license includes musculoskeletal disorders and several steroid microsphere combinations burlington mass july   globe newswire  flexion therapeutics inc nasdaqflxn today announced that it has executed  pdf add to briefcase file is in briefcase jul   flexion therapeutics announces board changes  sandesh sandy mahatme of sarepta therapeutics appointed new board member   flexion ceo michael clayman offers thanks to departing board member dr rafaéle tordjman  burlington mass july   globe newswire  flexion therapeutics inc nasdaqflxn announced today changes to the composition of its board of directors sandesh pdf add to briefcase file is in briefcase jun   flexion therapeutics announces positive topline results from phase a pharmacokinetic trial with lead compound fx  following intraarticular injection sustained release of triamcinolone acetonide tca from fx maintained therapeutic concentration levels in knee joints of patients through  weeks  pharmacokinetic pk data support previously completed phase b doseranging efficacy trial that demonstrated superior magnitude and duration of pain relief o pdf add to briefcase file is in briefcase jun   flexion therapeutics announces changes to board of directors  pathogenetix president  ceo ann merrifield appointed new board member  flexion ceo michael clayman offers thanks to departing board members bradley bolzon and elaine jones  burlington mass june   globe newswire  flexion therapeutics inc nasdaqflxn announced today recent changes to its board of directors ann merrifield pdf add to briefcase file is in briefcase jun   flexion therapeutics to present at wells fargo securities research economics  strategy  healthcare conference burlington mass june   globe newswire  flexion therapeutics inc nasdaqflxn today announced that ceo michael clayman md will present at the wells fargo securities research economics  strategy  healthcare conference at  pm eastern time on wednesday june   at the intercontinental hotel in boston to acces pdf add to briefcase file is in briefcase may   flexion therapeutics to present at the  jefferies healthcare conference burlington mass may   globe newswire  flexion therapeutics inc nasdaqflxn today announced that ceo michael clayman md will present an overview of the company at the  jefferies healthcare conference dr claymans presentation is scheduled for june   at  am eastern time the conference will take place june  pdf add to briefcase file is in briefcase may   flexion therapeutics reports firstquarter  financial results key highlightscompleted enrollment of fx phase a synovial fluid pharmacokinetics clinical trial with topline data expected in q initiated confirmatory fx phase b clinical trial to determine an optimal safe and efficacious dose compared to placebo added key personnel in quality assurance and regulatory affairs significantly bolstered ca pdf add to briefcase file is in briefcase may   flexion therapeutics to report first quarter  financial results on may   burlington mass may   globe newswire  flexion therapeutics inc nasdaqflxn announced today that it will host a conference call and webcast to report its first quarter  financial results on thursday may   at  pm et the dialin number for the conference call is tollfree   for domestic participants pdf add to briefcase file is in briefcase apr   flexion therapeutics initiates a phase b confirmatory doseranging trial with lead compound fx burlington mass april   globe newswire  flexion therapeutics inc nasdaqflxn announced today that the first patient has been dosed in a confirmatory phase b clinical trial designed to further evaluate the safety tolerability and efficacy of certain doses of fx as a treatment for relieving pain associated with oa of the knee  pdf add to briefcase file is in briefcase apr   flexion therapeutics to present at the th annual needham healthcare conference burlington mass april   globe newswire  flexion therapeutics inc nasdaqflxn today announced that ceo michael clayman md will present an overview of the company at the th annual needham healthcare conference dr claymans presentation is scheduled for april   at  pm eastern time the conference will take place a pdf add to briefcase file is in briefcase mar   flexion reports yearend  financial results  strong cash position bolstered with additional  million from ipo  lead drug candidate fx planned to enter into confirmatory phase b trial in osteoarthritis of the knee   second clinical candidate fx expected to enter phase  proofofconcept trial later in   burlington mass march   globe newswire  flex pdf add to briefcase file is in briefcase mar   flexion therapeutics to report yearend  earning results on march   burlington mass march   globe newswire  flexion therapeutics inc nasdaqflxn announced today that it will host a conference call and webcast to report its yearend  financial results on thursday march   at  pm et the dialin number for the conference call is   for domestic participants and   pdf add to briefcase file is in briefcase feb   flexion therapeutics to present at the th annual cowen health care conference burlington mass feb   globe newswire  flexion therapeutics inc nasdaqflxn today announced that ceo michael clayman md will present an overview of the company at the th annual cowen health care conference dr claymans presentation is scheduled for march   at  pm eastern time the conference will take place ma pdf add to briefcase file is in briefcase feb   flexion therapeutics announces closing of initial public offering and full exercise of underwriters option to purchase additional shares burlington mass feb   globe newswire  flexion therapeutics inc nasdaqflxn announced today the closing of its initial public offering of  shares of its common stock at an initial public offering price of  per share which includes the exercise in full by the underwriters of their option to purchase up to  ad pdf add to briefcase file is in briefcase feb   flexion therapeutics announces pricing of initial public offering burlington mass feb   globe newswire  flexion therapeutics inc nasdaqflxn announced today the pricing of its initial public offering of  shares of common stock at a price to the public of  per share the shares are scheduled to begin trading on the nasdaq global market under the ticker symbol flxn on february  pdf add to briefcase file is in briefcase jan   flexion therapeutics files registration statement for proposed initial public offering burlington mass january    flexion therapeutics inc announced today that it has filed a registration statement on form s with the us securities and exchange commission sec for a proposed initial public offering of shares of its common stock  all of the shares to be sold in the offering will be offered by flexion t pdf add to briefcase file is in briefcase oct   flexion therapeutics presents robust phase b data for fx at  american college of rheumatology annual scientific meeting burlington mass october     flexion therapeutics inc announced today that new data from a phase b doseranging clinical trial of the companys lead compound fx were presented at the   american college of rheumatolog pdf add to briefcase file is in briefcase oct   flexion therapeutics to present phase b data for fx at  american college of rheumatology annual scientific meeting burlington mass october    flexion therapeutics inc announced today that new data from a phase b doseranging trial of the companys lead compound fx in osteoarthritis oa has been accepted for an oral presentation at the  annual scientific meeting of the american co pdf add to briefcase file is in briefcase jun   flexion’s fx demonstrates superior pain relief compared to standardofcare in phase b osteoarthritis trial burlington mass june    flexion therapeutics inc today reported that its lead compound fx a novel intraarticular ia sustained release steroid demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release s pdf add to briefcase file is in briefcase may   flexion therapeutics names frederick driscoll chief financial officer woburn mass may     flexion therapeutics inc today announced the addition of frederick w driscoll to its management team as chief financial officer mr driscoll has more than  years of financial management experience with biotechnology and medical device companies p pdf add to briefcase file is in briefcase apr   data presented at oarsi’s  world congress on osteoarthritis show flexion’s fx has prolonged therapeutic concentration in knee joint woburn mass april     flexion therapeutics inc announced today the presentation of a poster titled fx prolongs the residency of triamcinolone acetonide in the synovial tissues of patients with knee osteoarthritis at osteoarthritis research society internationals oarsi  pdf add to briefcase file is in briefcase jan   flexion therapeutics to present at st annual jp morgan healthcare conference pdf add to briefcase file is in briefcase dec   flexions fx achieves prolonged therapeutic concentrations in joints of osteoarthritis patients pdf add to briefcase file is in briefcase dec   flexion therapeutics secures  million in series b financing pdf add to briefcase file is in briefcase jun   flexion therapeutics names arthur fratamico chief business officer pdf add to briefcase file is in briefcase jan   flexion therapeutics announces agreements with four major pharmaceutical companies pdf add to briefcase file is in briefcase oct   flexion therapeutics raises  million in series a financing pdf add to briefcase file is in briefcase  add release to briefcase news press releases briefcase printed materials email alerts downloads snapshot rss print share facebook google linkedin twitter email rss nasdaq flxn     day high  day low   volume      pm et on jul   delayed  min by esignal   flexion therapeutics inc infoflexiontherapeuticscom  website design  development by graphic beans terms of use privacy policy sitemap investors  flexion therapeutics inc new paradigms for the treatment of pain investors flexion is a specialty pharmaceutical company focused on the development and commercialization of novel local therapies for the treatment of patients with musculoskeletal conditions beginning with osteoarthritis oa the companys lead product candidate zilretta™ fx is an extended release intraarticular analgesic candidate in late stage development for moderate to severe osteoarthritis pain press releases jul   flexion therapeutics to hold investor  analyst day today jul   flexion therapeutics to hold investor and analyst day on july   view all press releases » events  presentations jul   at  am et flexion analyst day may   at  pm et flexion therapeutics q  earnings call view all events  presentations » investors events  presentations corporate governance management board of directors committee composition contact the board financials  filings sec filings annual reports and proxies quarterly results key ratios stock information historic stock lookup investment calculator ownership profile analyst coverage contact us briefcase printed materials email alerts downloads snapshot rss print share facebook google linkedin twitter email rss nasdaq flxn     day high  day low   volume      pm et on jul   delayed  min by esignal   flexion therapeutics inc infoflexiontherapeuticscom  website design  development by graphic beans terms of use privacy policy sitemap